Want to join the conversation?
$GIII now expects FY17 non-GAAP EPS of $2.20-2.30 and adjusted EBITDA to decline 2-3% to about $199-206MM. Adjusted EBITDA for FY17 does not reflect the significant additional expenses related to this acquisition of Donna Karan that the company expects to incur 2H17.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)